Nirogacestat (Ogsiveo): A Comprehensive Monograph on a First-in-Class Gamma-Secretase Inhibitor for Desmoid Tumors

Executive Summary

Nirogacestat, marketed as Ogsiveo, is a first-in-class, oral, selective gamma-secretase inhibitor that represents a landmark therapeutic advance for the treatment of desmoid tumors. Its approval by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) addresses a long-standing unmet medical need for a dedicated, mechanism-based therapy for this rare and debilitating condition. Nirogacestat functions by inhibiting the gamma-secretase enzyme complex, thereby blocking the activation of the Notch signaling pathway, which is aberrantly activated in desmoid tumors and contributes to their growth. The pivotal Phase 3 DeFi clinical trial demonstrated profound and statistically significant efficacy, with nirogacestat reducing the risk of disease progression or death by 71% compared to placebo. This was accompanied by a high objective response rate and meaningful improvements in patient-reported outcomes, including pain and overall quality of life. The safety profile is characterized by a set of common, manageable adverse events and notable class-related toxicities, particularly ovarian toxicity, which requires careful patient counseling. The drug's pharmacology is also defined by a secondary mechanism involving the modulation of B-cell maturation antigen (BCMA), which has positioned it as a promising combination agent for enhancing BCMA-targeted therapies in multiple myeloma. As a Category 1 recommended therapy in NCCN guidelines, nirogacestat has established a new standard of care for adult patients with progressing desmoid tumors requiring systemic treatment.

Introduction to Desmoid Tumors and the Therapeutic Landscape

Pathophysiology and Clinical Presentation of Desmoid Tumors (Aggressive Fibromatosis)

Desmoid tumors (DTs), also known as aggressive fibromatosis, are rare soft tissue neoplasms characterized by the clonal proliferation of fibroblastic cells.[1] Despite being histologically benign and non-metastasizing, they exhibit a locally aggressive and infiltrative growth pattern that can cause significant morbidity.[3] The clinical presentation varies widely depending on tumor location and size, but common consequences include severe pain, disfigurement, functional impairment, and disability.[4] In rare instances where tumors impinge upon vital organs or structures, they can be life-threatening.[3] The annual incidence in the United States is estimated to be between 1,000 and 1,650 new cases, with a two-to-three times higher prevalence in females, most commonly diagnosed between the ages of 20 and 44.[3]

The molecular pathogenesis of DTs is well-characterized. The majority of cases (over 90%) are sporadic and are driven by somatic mutations in the CTNNB1 gene, which encodes β-catenin.[2] A smaller subset (10-15%) is associated with the genetic syndrome Familial Adenomatous Polyposis (FAP), caused by germline mutations in the

APC gene.[2] Both genetic alterations lead to the dysregulation of the Wnt/β-catenin signaling pathway, a critical driver of cellular proliferation.[7] In addition to Wnt pathway activation, a key characteristic of DTs is the aberrant activation of the Notch signaling pathway, another highly conserved system that regulates cell fate, proliferation, and survival.[1] This dual pathway dysregulation provides a strong biological rationale for the development of targeted therapies. The clinical course of DTs is notably unpredictable; some tumors may remain stable or even regress spontaneously, while others progress aggressively, complicating treatment decisions and underscoring the need for effective systemic options for patients with advancing disease.[2]

Evolution of Treatment Paradigms: From Surgery to Systemic Therapies

The management of desmoid tumors has undergone a significant paradigm shift over the past two decades. Historically, surgical resection was considered the primary treatment modality.[3] However, this approach is now largely disfavored due to unacceptably high local recurrence rates, which can be as high as 77% even following complete resection with clear margins.[3] The invasive nature of the tumors often makes achieving negative margins challenging, and there is evidence to suggest that surgical trauma itself may promote tumor recurrence.[12]

In recognition of these limitations and the potential for spontaneous regression, contemporary treatment guidelines from authoritative bodies such as the National Comprehensive Cancer Network (NCCN) and the Desmoid Tumor Working Group (DTWG) recommend active surveillance as the initial front-line approach for most patients with asymptomatic or non-progressing tumors.[11] For patients with documented tumor progression or significant symptoms, systemic therapies are now recommended as a first-line treatment option.[12] This evolution in clinical practice has created a clear and urgent need for effective, safe, and well-tolerated systemic agents that can provide durable disease control.

Unmet Needs and the Rationale for Targeting Gamma-Secretase

Prior to November 2023, there were no therapies specifically approved by the FDA for the treatment of desmoid tumors.[3] The therapeutic landscape consisted of off-label use of various systemic agents, including cytotoxic chemotherapy (e.g., doxorubicin, methotrexate/vinblastine), multi-targeted tyrosine kinase inhibitors (TKIs) (e.g., sorafenib, pazopanib, imatinib), and hormonal therapies.[2] While these treatments offer some benefit, their efficacy is variable, and they are often associated with significant toxicity profiles that can limit long-term use.[11]

The identification of aberrant Notch signaling as a key driver of DT pathogenesis provided a compelling rationale for a more targeted therapeutic strategy.[8] The Notch receptor requires proteolytic cleavage by the gamma-secretase enzyme complex for its activation.[1] Therefore, inhibiting this enzyme presents a direct and logical approach to disrupting the pathological signaling cascade.[18] The development of nirogacestat as a selective gamma-secretase inhibitor was based on this premise, aiming to provide a mechanism-based therapy that could address the long-standing unmet medical need for a dedicated, approved treatment with a well-characterized efficacy and safety profile for this specific disease.[14]

Nirogacestat: Chemical Profile and Drug Development

Chemical Identity and Physicochemical Properties

Nirogacestat is a small molecule drug classified as a member of tetralins, an organofluorine compound, a secondary carboxamide, a secondary amino compound, and a member of imidazoles.[8] Its chemical and physical properties are well-defined, providing a foundation for its pharmacological activity.

Table 1: Nirogacestat Drug Profile Summary

Parameter	Value
Brand Name	Ogsiveo
Generic Name	Nirogacestat
DrugBank ID	DB12005 8
Type	Small Molecule 8
CAS Number	1290543-63-3 (free base) 8
IUPAC Name	(2S)-2-amino]-N-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide 8
Molecular Formula	C27​H41​F2​N5​O (free base) 8
Molecular Weight	489.66 g/mol (free base) 21
UNII	QZ62892OFJ 8
InChIKey	VFCRKLWBYMDAED-REWPJTCUSA-N 8
SMILES	CCCC@@HN[C@H]2CCC3=C(C2)C(=CC(=C3)F)F
XlogP	4.8
Topological Polar Surface Area (TPSA)	71 A˚2
Hydrogen Bond Donors	3
Hydrogen Bond Acceptors	6

Developmental History and Regulatory Milestones

The development journey of nirogacestat exemplifies a successful model of collaboration in advancing therapies for rare diseases. The compound, originally designated PF-03084014, was first synthesized and investigated by Pfizer. While early Phase 1 trial data was generated, the development for the rare indication of desmoid tumors gained critical momentum when the results captured the attention of investigators at the National Cancer Institute (NCI). This led to a crucial collaboration between Pfizer and the NCI to conduct a Phase 2 trial, a study that would have been challenging to execute at a single institution due to the rarity of the disease. This partnership was instrumental in generating the data needed to move the program forward and contributed to the establishment of the NCI's Rare Tumor Initiative.

Subsequently, SpringWorks Therapeutics, Inc. acquired the rights to nirogacestat and led its late-stage clinical development and regulatory submission process. This focused effort culminated in a series of major regulatory achievements. On November 27, 2023, the U.S. FDA approved nirogacestat under the brand name Ogsiveo for adult patients with progressing desmoid tumors who require systemic treatment. This marked a historic milestone, as it was the first therapy ever approved by the FDA for this indication. The high unmet medical need and the strength of the clinical data were recognized by the FDA through the granting of multiple expedited pathway designations, including Priority Review, Fast Track, Breakthrough Therapy, and Orphan-Drug designation.

Following its success in the U.S., SpringWorks pursued regulatory approval in Europe. The European Medicines Agency (EMA) granted Orphan Drug designation for nirogacestat, and the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in June 2025 (projected date). This led to the granting of marketing authorization by the European Commission on August 18, 2025 (projected date), making Ogsiveo the first and only approved therapy for desmoid tumors in the European Union.

Pharmacology of Nirogacestat

Mechanism of Action: Inhibition of Gamma-Secretase and the Notch Signaling Pathway

Nirogacestat is a potent, selective, reversible, and noncompetitive inhibitor of the gamma-secretase enzyme complex, with a half-maximal inhibitory concentration (IC50​) of 6.2 nM. Gamma-secretase is an intramembrane protease responsible for the cleavage of numerous transmembrane proteins, most notably the Notch receptors. Notch signaling is initiated when a Notch receptor binds to its ligand, triggering a series of proteolytic events. The final and critical step is the cleavage of the receptor within its transmembrane domain by gamma-secretase, which releases the Notch Intracellular Domain (NICD).

By inhibiting gamma-secretase, nirogacestat directly blocks this final cleavage step. This prevents the liberation of NICD, thereby halting its translocation to the nucleus and subsequent activation of target gene transcription. As these target genes are key regulators of cell proliferation, differentiation, and survival, the inhibition of this pathway leads to the disruption of tumor cell growth.

The molecular interaction between nirogacestat and its target has been elucidated with high resolution. Cryogenic electron microscopy studies have shown that nirogacestat localizes within the catalytic subunit of the gamma-secretase complex, presenilin 1. It forms four specific hydrogen bonds with lysine and leucine residues (positions 380 and 432, respectively), aligning itself in a way that selectively obstructs the site of Notch cleavage. This precise, well-characterized binding mechanism provides a strong molecular basis for its targeted therapeutic action.

Secondary Mechanisms and Molecular Interactions (e.g., BCMA modulation)

Beyond its primary role in inhibiting Notch signaling for the treatment of desmoid tumors, nirogacestat possesses a secondary mechanism of action with significant therapeutic potential in hematologic malignancies. The gamma-secretase enzyme also cleaves B-cell maturation antigen (BCMA), a key therapeutic target expressed on the surface of multiple myeloma cells. This cleavage process releases a soluble form of BCMA (sBCMA) into the circulation. High levels of sBCMA can act as a "decoy," binding to and neutralizing BCMA-directed therapies such as antibody-drug conjugates (ADCs), CAR-T cells, and bispecific antibodies, thereby limiting their efficacy.

By inhibiting gamma-secretase, nirogacestat prevents the shedding of BCMA from the myeloma cell surface. This has two synergistic effects: it increases the density of the BCMA target on the cancer cell, and it reduces the concentration of interfering sBCMA decoys in the tumor microenvironment. This dual action is expected to potentiate or enhance the activity of BCMA-targeted therapies. This sophisticated therapeutic strategy has transformed nirogacestat from a single-indication agent into a potential combination partner for an entire class of immunotherapies in multiple myeloma. This potential has led to numerous clinical collaborations between SpringWorks Therapeutics and industry leaders to evaluate nirogacestat in combination with various BCMA-directed modalities.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of nirogacestat has been well-characterized in patients with desmoid tumors.

• Absorption: Nirogacestat is orally bioavailable. Following oral administration, it is rapidly absorbed, with a median time to peak plasma concentration ( Tmax​) of 1.5 hours. The absolute bioavailability is approximately 19%. Administration with food has a minimal effect on overall exposure (AUC), allowing it to be taken with or without food.
• Distribution: The drug exhibits an extensive apparent volume of distribution of 1430 L, indicating wide distribution into tissues. It is highly bound to plasma proteins (99.6%), primarily to serum albumin (94.6%) and α1-acid glycoprotein (97.9%).
• Metabolism: Nirogacestat is extensively metabolized, primarily via N-dealkylation mediated by the cytochrome P450 3A4 (CYP3A4) isoenzyme, which accounts for approximately 85% of its clearance. Minor metabolic pathways involve CYP2C19, CYP2C9, and CYP2D6. This heavy reliance on CYP3A4 is the basis for its numerous clinically significant drug-drug interactions.
• Excretion: The drug is eliminated through multiple routes, with 38% of a dose recovered in feces and 17% in urine. The mean terminal elimination half-life is approximately 23 hours, which supports a twice-daily dosing regimen. Steady-state concentrations are achieved in approximately 6 days of continuous dosing.

Pharmacodynamics: Exposure-Response Relationships

Pharmacodynamic analyses have established a clear relationship between nirogacestat exposure and certain clinical effects. A direct exposure-response relationship has been identified for the development of Grade 3 hypophosphatemia, with higher plasma concentrations of the drug correlating with an increased risk of this adverse event. This finding provides a strong rationale for dose reductions in patients who experience this toxicity or in those taking concomitant medications that increase nirogacestat exposure. Importantly, at the recommended therapeutic dosage, nirogacestat does not cause clinically significant prolongation of the QTc interval (mean increase < 20 ms), a favorable cardiovascular safety feature.

Clinical Efficacy in Desmoid Tumors

Preclinical and Early Phase Development

The clinical development of nirogacestat was built upon a strong preclinical foundation. In vivo studies using mouse tumor models demonstrated robust and dose-dependent antitumor activity, with maximal tumor growth inhibition reaching approximately 92% at higher dose levels. These promising preclinical results supported the transition to human trials. Early-phase clinical studies successfully established the safety profile, identified key toxicities for monitoring, and provided preliminary evidence of clinical activity in patients with desmoid tumors, which ultimately justified the initiation of the pivotal Phase 3 study. Further evaluation of the drug's activity is ongoing in a Phase 2 study (NCT05879146).

Pivotal Phase 3 DeFi Trial (NCT03785964): A Detailed Analysis

Study Design and Patient Population

The DeFi trial was a landmark study that established the efficacy and safety of nirogacestat. It was a global, multicenter, randomized (1:1), double-blind, placebo-controlled Phase 3 trial. The study enrolled 142 adult patients with histologically confirmed desmoid tumors that were not amenable to surgical resection. A critical inclusion criterion was documented tumor progression, defined as an increase in tumor size of at least 20% within the 12 months prior to screening. This rigorous criterion ensured that the trial population consisted of patients with actively growing disease who required systemic intervention, thereby strengthening the validity of the results by minimizing the confounding effect of spontaneous tumor regression. The study population was representative of the typical desmoid tumor demographic, with a median age in the mid-30s and a higher proportion of female patients. Patients were randomized to receive either nirogacestat 150 mg twice daily or a matching placebo.

Primary and Secondary Efficacy Endpoints (PFS, ORR)

The DeFi trial successfully met its primary and all key secondary endpoints, demonstrating a profound clinical benefit for nirogacestat.

• Progression-Free Survival (PFS): The trial met its primary endpoint of PFS. Treatment with nirogacestat resulted in a 71% reduction in the risk of disease progression or death compared to placebo, a highly statistically significant finding (Hazard Ratio = 0.29; 95% CI, 0.15-0.55; p<0.001). The median PFS was not reached in the nirogacestat arm, whereas it was 15.1 months in the placebo arm. At the 2-year time point, the estimated PFS rate was 76% for patients receiving nirogacestat versus 44% for those on placebo.
• Objective Response Rate (ORR): Nirogacestat also demonstrated a superior ability to shrink tumors. The ORR, a key secondary endpoint, was 41% in the nirogacestat arm compared to just 8% in the placebo arm (p<0.001). This result clearly distinguishes the drug's antitumor effect from the known background rate of spontaneous regression. Furthermore, 7% of patients treated with nirogacestat achieved a complete response (CR), meaning complete tumor disappearance, whereas no patients in the placebo group achieved a CR. This demonstrates that nirogacestat can induce deep and meaningful tumor regressions, not just disease stabilization.

Patient-Reported Outcomes: Impact on Pain and Quality of Life

For a non-metastatic but highly morbid disease like desmoid tumors, improvements in patient symptoms and quality of life are as critical as radiographic tumor responses. The DeFi trial incorporated comprehensive assessments of patient-reported outcomes (PROs) as secondary and exploratory endpoints. The results showed that patients treated with nirogacestat experienced early, statistically significant, and sustained improvements in pain—one of the most debilitating symptoms of the disease. In addition to pain reduction, patients in the nirogacestat arm also reported significant improvements in overall symptom burden, physical and role functioning, and global health-related quality of life compared to the placebo group. These PRO findings provide a holistic view of the drug's clinical value, demonstrating that its benefits extend beyond tumor measurements to produce meaningful improvements in patients' daily lives.

Subgroup Analyses and Long-Term Follow-up Data

The clinical benefit of nirogacestat was observed consistently across all prespecified patient subgroups, regardless of patient sex, tumor location, prior treatment history, or the underlying genetic mutation status (CTNNB1 or APC). This broad efficacy suggests that nirogacestat can be effectively used across the diverse spectrum of the adult desmoid tumor population without the need for biomarker-based patient selection.

Long-term follow-up data have further reinforced the durability of these benefits. Data with up to four years of treatment showed a confirmed ORR of 45.7%, with the complete response rate increasing to 11.4% over time. For patients with at least three years of treatment, the median best percentage change in tumor size was a reduction of 51.3%. These findings demonstrate that responses to nirogacestat are not only durable but can also deepen with continued therapy, providing confidence in its utility for the long-term management of this chronic disease.

Safety and Tolerability Profile

Overview of Common and Serious Adverse Reactions

The safety profile of nirogacestat was characterized in the DeFi trial. The most frequently reported adverse reactions were generally manageable, though some were notable for their high incidence.

Table 2: Incidence of Common Adverse Reactions (≥15%) from the DeFi Trial (Nirogacestat vs. Placebo)

Adverse Reaction	Nirogacestat (N=70) %	Placebo (N=72) %
Diarrhea	84	35
Ovarian Toxicity*	75	0
Rash	68	14
Nausea	54	39
Fatigue	54	38
Stomatitis	39	4
Headache	30	Not Reported
Abdominal Pain	22	14
Cough	20	Not Reported
Alopecia	19	1.4
Upper Respiratory Tract Infection	17	Not Reported
Dyspnea	16	Not Reported
*Data based on 36 females of reproductive potential in the nirogacestat arm.
Sources:

The most common laboratory abnormalities that worsened from baseline included decreased phosphate (65% vs 11%), decreased potassium (22% vs 4.2%), increased urine glucose (51% vs 0%), increased urine protein (40% vs 25%), increased AST (33% vs 18%), and increased ALT (30% vs 21%).

Management of Key Adverse Events: Diarrhea, Ovarian Toxicity, and Hypophosphatemia

While many side effects were mild to moderate, several key adverse events require specific monitoring and management strategies.

• Diarrhea: This was the most common adverse event, occurring in 84% of patients, with 16% experiencing Grade 3 (severe) events. The median time to onset was 9 days. Standard management with antidiarrheal medications is recommended, along with dose interruption or reduction for more severe cases.
• Ovarian Toxicity: This is a very common and clinically significant risk, particularly given that desmoid tumors disproportionately affect young women. Animal studies indicated a risk of ovarian atrophy, amenorrhea, and impaired fertility, some of which may be irreversible. In the DeFi trial, 75% of the 36 females of reproductive potential experienced ovarian toxicity. This can manifest as changes in menstrual cycle regularity or symptoms of estrogen deficiency (e.g., hot flashes, night sweats, vaginal dryness). It is imperative that female patients of reproductive potential are counseled on this risk before initiating therapy, and regular monitoring is recommended.
• Hypophosphatemia: Decreased phosphate levels occurred in 65% of patients. This is a known class effect of gamma-secretase inhibitors, potentially mediated by the downregulation of sodium phosphate transporters in the gut or kidneys. Regular monitoring of phosphate levels is necessary, with supplementation as needed and dose modification for severe cases.
• Other Serious Adverse Reactions: Other important risks include hepatotoxicity (elevations in liver transaminases), the development of non-melanoma skin cancers (cutaneous squamous cell carcinoma and basal cell carcinoma), and embryo-fetal toxicity (based on animal data, which showed embryo-fetal death at exposures below the human dose).

Warnings, Precautions, and Contraindications

The official prescribing information for Ogsiveo lists no absolute contraindications. However, it includes a comprehensive set of warnings and precautions that necessitate careful patient monitoring. These warnings highlight the risks of:

• Diarrhea
• Ovarian Toxicity
• Hepatotoxicity
• Non-Melanoma Skin Cancers
• Electrolyte Abnormalities (hypophosphatemia, hypokalemia)
• Embryo-Fetal Toxicity

These warnings underscore the need for baseline and ongoing monitoring of blood counts, electrolytes, and liver function, as well as regular dermatologic evaluations and pregnancy testing for females of reproductive potential.

Dosing, Administration, and Practical Considerations

Recommended Dosing and Administration Guidelines

The recommended dosage of Ogsiveo is 150 mg administered orally twice daily. The medication is supplied as 50 mg, 100 mg, and 150 mg film-coated tablets to facilitate dose adjustments. Ogsiveo can be taken with or without food. Patients should be instructed to swallow the tablets whole and not to break, crush, or chew them. In the event of a missed dose or if a patient vomits after taking a dose, they should not take a make-up dose but rather take the next dose at its regularly scheduled time.

Dose Modifications for Adverse Reactions

To manage treatment-related toxicities, the prescribing information provides specific guidelines for dose reduction and interruption. The first dose reduction level is to 100 mg twice daily.

Table 3: Dose Modification Guidelines for Key Adverse Reactions

Adverse Reaction	Severity (Grade)	Recommended Action
Diarrhea	Grade 2 (intolerable) or Grade 3	Withhold OGSIVEO until recovery to ≤ Grade 1. Resume at the same or a reduced dose.
ALT or AST Elevation	Grade 2 (>3 to 5 x ULN)	Withhold OGSIVEO until recovery to baseline. Resume at the same dose. If recurs, resume at a reduced dose.
	Grade 3 (>5 to 20 x ULN)	Withhold OGSIVEO until recovery to baseline. Resume at a reduced dose. Permanently discontinue for recurrence.
	>20 x ULN	Permanently discontinue OGSIVEO.
Hypophosphatemia	Grade 3 (<2 to 1 mg/dL)	Withhold OGSIVEO until recovery to baseline. Resume at the same or a reduced dose.
	Grade 4 (<1 mg/dL)	Withhold OGSIVEO until recovery to baseline. Resume at a reduced dose.
Source:

Permanent discontinuation is recommended if a severe or life-threatening adverse reaction recurs upon rechallenge at a reduced dose.

Clinically Significant Drug and Food Interactions

The pharmacokinetic profile of nirogacestat gives rise to several clinically important interactions that require careful management.

Table 4: Clinically Significant Drug Interactions

Interacting Agent Class	Mechanism	Clinical Recommendation
Strong or Moderate CYP3A Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)	Increase nirogacestat plasma concentrations, increasing the risk of toxicity.	Avoid concomitant use.
Strong or Moderate CYP3A Inducers (e.g., rifampin, carbamazepine, St. John’s Wort)	Decrease nirogacestat plasma concentrations, potentially reducing efficacy.	Avoid concomitant use.
Grapefruit, Seville Oranges, Starfruit	Potent CYP3A inhibitors.	Avoid consumption during treatment.
Gastric Acid Reducing Agents (Proton Pump Inhibitors, H2 Blockers)	Increase gastric pH, which may decrease nirogacestat solubility and absorption, potentially reducing efficacy.	Avoid concomitant use with PPIs and H2 blockers.
Antacids	Increase gastric pH.	Stagger administration: take OGSIVEO 2 hours before or 2 hours after antacid use.
Source:

These interactions represent a significant practical challenge, as many of the interacting drugs are commonly prescribed. Thorough medication reconciliation and patient education are essential to ensure the safe and effective use of nirogacestat.

Comparative Analysis and Place in Therapy

Positioning of Nirogacestat within NCCN and Global Treatment Guidelines

Following its landmark approval and the robust data from the DeFi trial, nirogacestat has been rapidly incorporated into major clinical practice guidelines. The NCCN guidelines for Soft Tissue Sarcoma now list nirogacestat as a preferred, Category 1 treatment option for patients with desmoid tumors that are progressing and/or causing symptoms. A Category 1 recommendation signifies the highest level of evidence and a uniform consensus that the intervention is appropriate. This high-level endorsement solidifies nirogacestat's position as a new standard of care for its indicated population and is expected to drive its widespread adoption in clinical practice.

Comparative Efficacy and Safety Profile vs. Other Systemic Therapies

While direct head-to-head comparative trials are not available, a cross-trial comparison of data from key studies provides context for nirogacestat's efficacy and safety relative to other systemic therapies used off-label for desmoid tumors.

Table 5: Comparative Overview of Systemic Therapies for Desmoid Tumors

Therapy	Drug Class	Mechanism	Key Efficacy Data (PFS / ORR)	Key Toxicities
Nirogacestat	GSI	Notch pathway inhibition	2-yr PFS: 76%; ORR: 41%	Diarrhea, Ovarian Toxicity, Hypophosphatemia, Rash
Sorafenib	TKI	Multi-kinase inhibition	2-yr PFS: 81%; ORR: 33%	Rash, Hypertension, Diarrhea, Fatigue, Hand-foot syndrome
Pazopanib	TKI	Multi-kinase inhibition	6-mo non-PD rate: 86%; ORR: 37%	Hypertension, Diarrhea, Fatigue, Hepatotoxicity
Imatinib	TKI	Multi-kinase inhibition	2-yr PFS: 55%; ORR: ~3-19%	Edema, Nausea, Fatigue, Rash, Myelosuppression
Methotrexate + Vinblastine	Chemotherapy	Antimetabolite + Vinca alkaloid	5-yr PFS: ~81%; ORR: ~47%	Myelosuppression, Neuropathy, Stomatitis, Hepatotoxicity

This comparison indicates that nirogacestat's efficacy, particularly its ORR of 41% and the 71% reduction in risk of progression, is highly competitive with the most active agents available, such as sorafenib and low-dose chemotherapy. The primary differentiating factors in clinical decision-making will likely be the specific safety profiles. While TKIs are associated with cardiovascular toxicities like hypertension and hand-foot syndrome, nirogacestat's profile is dominated by gastrointestinal effects, hypophosphatemia, and, most notably, ovarian toxicity. The high rate of ovarian toxicity is a critical consideration that distinguishes it from other options and will be a central point of discussion with young female patients.

Future Directions and Investigational Uses

Ongoing and Planned Studies in Desmoid Tumors

The clinical development of nirogacestat in desmoid tumors is ongoing. An open-label extension of the DeFi trial continues to provide long-term data on the drug's durability and safety. A critical next step is the evaluation of nirogacestat in younger patients. A Phase 2 study in collaboration with the Children's Oncology Group is currently investigating its use in pediatric patients with desmoid tumors, which could potentially expand its indication to this important population.

Exploration in Other Malignancies

The therapeutic potential of nirogacestat extends beyond desmoid tumors, driven by its dual mechanisms of action.

• Ovarian Granulosa Cell Tumors: A Phase 2 study (NCT05348356) is currently evaluating nirogacestat as a monotherapy for patients with recurrent ovarian granulosa cell tumors, another cancer type where Notch signaling may play a pathogenic role.
• Multiple Myeloma: The most significant area of investigation is in multiple myeloma. Based on the strong scientific rationale for its ability to potentiate BCMA-targeted therapies, nirogacestat is being evaluated in numerous combination therapy regimens with industry and academic partners. These collaborations span multiple therapeutic modalities, including ADCs, CAR-T cell therapies, and bispecific antibodies. Success in these trials could fundamentally reposition nirogacestat as a cornerstone combination agent in the treatment of a major hematologic malignancy.

The Next Generation of Gamma-Secretase and Wnt Pathway Inhibitors

The success of nirogacestat has validated gamma-secretase as a druggable and clinically relevant target in oncology. This has spurred further investment in the field. Other gamma-secretase inhibitors, such as AL102, are now in late-stage clinical development for desmoid tumors and may represent future competition. Additionally, novel agents targeting the parallel Wnt pathway, such as Tegavivint, are also under investigation, promising a future therapeutic landscape with multiple targeted options for patients with this disease.

Conclusion

Nirogacestat (Ogsiveo) is a transformative, first-in-class gamma-secretase inhibitor that has established a new standard of care for adult patients with progressing desmoid tumors. Its approval was based on unequivocal evidence of clinical benefit from the pivotal Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival, a high objective response rate, and meaningful gains in patient-reported pain and quality of life. The drug's targeted mechanism of action, which disrupts the pathogenic Notch signaling pathway, represents a significant advance over previously used non-specific, off-label therapies.

While its safety profile includes common and manageable adverse events, it is also characterized by significant class-related toxicities, most notably a high rate of ovarian toxicity, which necessitates careful patient selection and comprehensive counseling. The drug's pharmacology, particularly its reliance on CYP3A4 metabolism, also requires diligent management of drug and food interactions. Beyond its primary indication, nirogacestat's unique ability to modulate BCMA expression has positioned it as a highly promising agent for combination therapy in multiple myeloma, opening a significant avenue for future development. In summary, nirogacestat is a landmark achievement in rare disease therapy, providing a much-needed, effective treatment for desmoid tumor patients and serving as a successful model for targeted drug development.

Works cited

1. What is the mechanism of Nirogacestat? - Patsnap Synapse, accessed September 8, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-nirogacestat
2. Desmoid Tumors: Current Perspective and Treatment - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10873447/
3. SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors, accessed September 8, 2025, https://springworkstx.gcs-web.com/news-releases/news-release-details/springworks-therapeutics-announces-new-england-journal-medicine/
4. FDA Approves Nirogacestat, the First-Ever Targeted Therapy for Desmoid Tumors, accessed September 8, 2025, https://www.mskcc.org/news/nirogacestat-new-desmoid-tumor-treatment-improves-outcomes-people-sarcoma
5. SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors, accessed September 8, 2025, https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-nirogacestat-achieved-primary/
6. FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors, accessed September 8, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-type-non-cancerous-tumors
7. Surgical Management of Desmoid Tumors—Patient Selection, Timing, and Approach - MDPI, accessed September 8, 2025, https://www.mdpi.com/1718-7729/32/7/408
8. Nirogacestat | C27H41F2N5O | CID 46224413 - PubChem, accessed September 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Nirogacestat
9. First FDA-approved Treatment for Desmoid Tumors | AACR, accessed September 8, 2025, https://www.aacr.org/patients-caregivers/progress-against-cancer/first-fda-approved-treatment-for-desmoid-tumors/
10. Desmoid tumors - Diagnosis and treatment - Mayo Clinic, accessed September 8, 2025, https://www.mayoclinic.org/diseases-conditions/desmoid-tumors/diagnosis-treatment/drc-20446388
11. Treatment & Monitoring - The Desmoid Tumor Research Foundation, accessed September 8, 2025, https://dtrf.org/about-desmoid-tumors/treatment-monitoring/
12. Desmoid Tumor Treatment | OGSIVEO®(nirogacestat) HCP Site, accessed September 8, 2025, https://www.ogsiveo.com/hcp/desmoid-tumor-treatment/
13. Approaches To Desmoid Tumor Management For HCPs, accessed September 8, 2025, https://www.desmoidtumors.com/hcp/management/
14. Nirogacestat—the pathway to approval of the first treatment for desmoid tumors, a rare disease - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11815814/
15. Clinical Trials Archives - The Desmoid Tumor Research Foundation, accessed September 8, 2025, https://dtrf.org/about-dtrf/news-updates/category/clinical-trials/
16. TX HHSC New Drug Information, accessed September 8, 2025, https://www.hhs.texas.gov/sites/default/files/documents/apr-2024-durb-agenda-item8d.pdf
17. 9 Desmoid Tumor Treatment Options To Consider | MyDesmoidTumorTeam, accessed September 8, 2025, https://www.mydesmoidtumorteam.com/resources/desmoid-tumor-treatment-options-to-consider
18. go.drugbank.com, accessed September 8, 2025, https://go.drugbank.com/drugs/DB12005#:~:text=Nirogacestat%20is%20a%20gamma%20secretase,that%20contribute%20to%20tumor%20growth.
19. Nirogacestat - NCI - Division of Cancer Treatment and Diagnosis, accessed September 8, 2025, https://dctd.cancer.gov/drug-discovery-development/reagents-materials/formulary/about/agents/nirogacestat
20. Nirogacestat - Wikipedia, accessed September 8, 2025, https://en.wikipedia.org/wiki/Nirogacestat
21. Nirogacestat free base | PF-03084014 | CAS#1290543-63-3 | Gamma Secretase Inhibitor, accessed September 8, 2025, https://www.medkoo.com/products/9943
22. Compound: NIROGACESTAT (CHEMBL1770916) - ChEMBL - EMBL-EBI, accessed September 8, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1770916
23. Nirogacestat (PF-3084014) | γ-Secretase Inhibitor | MedChemExpress, accessed September 8, 2025, https://www.medchemexpress.com/PF-3084014.html
24. Nirogacestat: First Approval - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/38409573/
25. SpringWorks Therapeutics Announces Clinical Collaboration with PfizerInc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma | Pfizer, accessed September 8, 2025, https://www.pfizer.com/news/press-release/press-release-detail/springworks-therapeutics-announces-clinical-collaboration
26. FDA approves nirogacestat for desmoid tumors | FDA, accessed September 8, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nirogacestat-desmoid-tumors
27. OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson, accessed September 8, 2025, https://www.mckesson.com/about-us/newsroom/press-releases/2023/ogsiveo-fda-approved-for-desmoid-tumors/
28. Nirogacestat: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 8, 2025, https://go.drugbank.com/drugs/DB12005
29. Nirogacestat Receives European Approval for Treatment of Desmoid Tumors, accessed September 8, 2025, https://www.cancernetwork.com/view/nirogacestat-receives-european-approval-for-treatment-of-desmoid-tumors
30. Ogsiveo | European Medicines Agency (EMA), accessed September 8, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ogsiveo
31. European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors | SpringWorks Therapeutics, accessed September 8, 2025, https://ir.springworkstx.com/news-releases/news-release-details/european-commission-grants-approval-ogsiveor-nirogacestat/
32. OGSIVEO (Nirogacestat) Receives European Commission Approval for Desmoid Tumor Treatment - OncoDaily, accessed September 8, 2025, https://oncodaily.com/oncolibrary/ogsiveo-nirogacestat-ec-approval
33. Nirogacestat | 1290543-63-3 - ChemicalBook, accessed September 8, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB42628246.htm
34. Nirogacestat (Ogsiveo) Updates 2025: Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily, accessed September 8, 2025, https://oncodaily.com/drugs/nirogacestat-ogsiveo
35. Dosing & Mechanism of Action | HCP Site - OGSIVEO.com, accessed September 8, 2025, https://www.ogsiveo.com/hcp/ogsiveo-nirogacestat/
36. Nirogacestat and Hypophosphatemia - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10334393/
37. SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting, accessed September 8, 2025, https://springworkstx.gcs-web.com/news-releases/news-release-details/springworks-therapeutics-highlights-nirogacestat-clinical-data/
38. SpringWorks Therapeutics Announces FDA Approval of OGSIVEO ..., accessed September 8, 2025, https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-fda-approval-ogsiveotm/
39. Nirogacestat Recruiting Phase 2 Trials for Tumor Treatment | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB12005/clinical_trials?conditions=DBCOND0029676&phase=2&purpose=treatment&status=recruiting
40. Nirogacestat Completed Phase 3 Trials for Desmoid Tumor Treatment | DrugBank Online, accessed September 8, 2025, https://go.drugbank.com/drugs/DB12005/clinical_trials?conditions=DBCOND0028471&phase=3&purpose=treatment&status=completed
41. What is OGSIVEO? | OGSIVEO® (nirogacestat) Patient Site, accessed September 8, 2025, https://www.ogsiveo.com/what-is-ogsiveo/
42. FDA Approves Nirogacestat for Desmoid Tumors - OncLive, accessed September 8, 2025, https://www.onclive.com/view/fda-approves-nirogacestat-for-desmoid-tumors
43. OGSIVEO® (nirogacestat) | Official HCP Website, accessed September 8, 2025, https://www.ogsiveo.com/hcp/
44. OGSIVEO® (nirogacestat) | Official Patient Site, accessed September 8, 2025, https://www.ogsiveo.com/
45. PATIENT INFORMATION OGSIVEO (og-SIH-vee-oh) (nirogacestat) tablets What is OGSIVEO? OGSIVEO is a prescription medication used to - SpringWorks Therapeutics, accessed September 8, 2025, https://springworkstx.com/wp-content/uploads/2024/03/OGSIVEO-Patient-Information.pdf
46. Targeted Therapy, Sorafenib, Shows Promise as First-Line Treatment for Previously Untreatable Rare Tumors, accessed September 8, 2025, https://www.mskcc.org/news/targeted-therapy-sorafenib-shows-promise-first-line-treatment-previously-untreatable-rare-tumors
47. Sorafenib for Advanced and Refractory Desmoid Tumors - Rutgers Cancer Institute, accessed September 8, 2025, https://cinj.org/sites/cinj/files/documents/Sorafenib%20for%20Advanced%20and%20Refractory%20Desmoid%20Tumors.pdf
48. DESMOPAZ: Pazopanib slows disease progression of desmoid tumors - The Hospitalist, accessed September 8, 2025, https://blogs.the-hospitalist.org/content/desmopaz-pazopanib-slows-disease-progression-desmoid-tumors-0
49. DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group. - ASCO Publications, accessed September 8, 2025, https://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.11501
50. Pazopanib, a promising option for the treatment of aggressive fibromatosis - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/312531673_Pazopanib_a_promising_option_for_the_treatment_of_aggressive_fibromatosis
51. Pazopanib for progressive desmoid tumors - YouTube, accessed September 8, 2025, https://www.youtube.com/watch?v=s85_HoAFNQ4
52. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG) - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/28282612/
53. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up - PubMed, accessed September 8, 2025, https://pubmed.ncbi.nlm.nih.gov/20622000/
54. Gleevec (Imatinib) for Desmoid Tumor | MyDesmoidTumorTeam, accessed September 8, 2025, https://www.mydesmoidtumorteam.com/treatments/gleevec
55. Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial - PMC, accessed September 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7648024/
56. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis | Request PDF - ResearchGate, accessed September 8, 2025, https://www.researchgate.net/publication/317222642_Long-term_Efficacy_of_Methotrexate_Plus_VinblastineVinorelbine_in_a_Large_Series_of_Patients_Affected_by_Desmoid-Type_Fibromatosis
57. Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis, accessed September 8, 2025, https://www.cjcrcn.org/article/html_9758.html
58. New Treatments for Desmoid Tumors | MyDesmoidTumorTeam, accessed September 8, 2025, https://www.mydesmoidtumorteam.com/resources/new-treatments-for-desmoid-tumors